Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 380 employees. About 70% of the employees and projects are externally funded. Read more
See introductory video with welcome to the ICR
Katarzyna (Kasia) Gajewska, a researcher in Marina Vietri’s project group at Institute for Cancer Research, has been awarded a grant of 2 MNOK under the “radical ideas” programme of the Research Council of Norway.
Her project is named “Under Pressure: Mechanosensitive Nuclear Bodies in Cancer Progression”
Cancer cells experience intense physical stress as they grow and invade surrounding tissues, yet how these forces affect the cell nucleus is not fully understood.
Recommended sites for current OUS research news:
From Oslo University Hospital, in Norwegian:
OUS Innsikt – ny forskning, innovasjon og behandling - channel for science communication
More news from OUS (oslo-universitetssykehus.no)
From UiO and centres of excellence (UiO/OUS):
News from the Inst. of Clinical Medicine, UiO
Research news - UiO
CanCell - Centre for Cancer Cell Reprogramming
Cresco - Centre for Embryology and Healthy Development
PRIMA - Precision Immunotherapy Alliance - Norwegian version
Hybrid Technology Hub - Centre for Organ on a Chip-Technology
Announcement from the UiO Growth House:
Do you have an innovative idea based on your research for a new product or service, but need funding to develop your early-stage technology or service further?
Complete information:
Apply for seed funding NOK 50 000 or 200 000 from The UiO Growth House! (uio.no)
We have allocated NOK 1,5 million for this call. The application deadline is 1 September 2026.
Project leader Marina Vietri in Harald Stenmark’s group at Institute for Cancer Research has received a grant from the South-Eastern Norway Regional Health Authority (Helse Sør-Øst) of 9 MNOK on the project “Uncovering hidden nuclear vulnerabilities: from mechanism to anticancer strategies."
In this project, Vietri and her co-workers will investigate a newly identified cellular mechanism that appears to help cancer cells withstand stress. By understanding how this process functions and how it contributes to cancer cell survival, the aim is to identify new opportunities for improving cancer treatment. The long-term goal is to generate knowledge that may support the development of more effective therapeutic strategies and contribute to better outcomes for patients with cancer.
On 11 June, Sigrun Aasland, Minister of Research and Higher Education, launched the University of Oslo’s research strategy on emerging technologies. This long-term initiative aims to bridge basic research and technological development, and the government has allocated 25 million NOK to the University of Oslo in 2026 and 50 million NOK annually from 2027 to support its development. The initiative will be evaluated in 2030.
Altogether, this technology initiative comprises eight new research projects. Johanna Olweus will lead the project AI-Facilitated Immune Receptor Engineering (AFIRE), which will establish an integrated, AI-driven technology platform for the development of a new class of soluble and cell-based immune receptors targeting intracellular proteins.
Three Oslo University Hospital scientists received prestigous awards for their outstanding research on June 12th 2026.
The major prize - the "Excellent Researcher Award" - went to Kristina Haugaa.
Ida Lindeman and Nicola Pietro Montaldo both received the "Early Career Award".
The prize money - 400.000 and 200.000 NOK respectively - is earmarked for research activities.
The awards for outstanding research articles are awarded twice a year based on over 2,300 scientific articles that are published annually by OUS. The clinics' research committees nominate the articles, and an external committee evaluates and finally selects the six worthy winners.
The winning articles must have achieved international impact or have distinguished themselves in other ways. The articles must also be of exceptionally high quality and communicate important findings.
The prestigious interdisciplinary prize from the European Society for Radiotherapy and Oncology (ESTRO) honors outstanding research and significant contributions across disciplines within radiation oncology. The award highlights both the high quality of the research environment and the importance of interdisciplinary collaboration in the development of future cancer treatments.
This year, the prize was given to Heidi Lyng, head of the Clinical Radiation Biology group at the Institute for Cancer Research, for her work to understand the radiobiology of patient tumors and translate this knowledge into clinical practice.
